TrialThe Lancet. Oncology2013

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.

Jie Jin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.